Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.
N/A
18 Years
80 Years
18 Years
80 Years
Not Enrolling
Both
Hemoptysis
Both
Hemoptysis
Trial Information
Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.
This is a prospective observational study looking at some coagulation factors in individuals
with lung cancer. We are looking at BAL and plasma. We would like to see if there is a
difference in the levels and if this is the reason behind the higher incidence of hemoptysis
in patients with lung cancer.
Inclusion Criteria:
- Any patient scheduled to undergo bronchoscopy
Exclusion Criteria:
- Patients with evidence of coagulopathy either iatrogenic or the result of disease
process - coagulopathy defined as elevated prothrombin time, activated partial
thromboplastin time or platelet count less than 100,000
- Patients not scheduled to undergo bronchoalveolar lavage (BAL)
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Principal Investigator
Jijo John, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Oklahoma
Authority:
United States: Institutional Review Board
Study ID:
14455
NCT ID:
NCT00929565
Start Date:
June 2009
Completion Date:
October 2011
Related Keywords:
- Hemoptysis
- hemoptysis
- Hemoptysis
Name | Location |
|---|---|
| VA Medical Center | Oklahoma City, Oklahoma 73104 |
